Market Overview

Top 4 Small-Cap Stocks In The Diagnostic Substances Industry With The Highest Revenue

Related NEOG
Earnings Scheduled For March 21, 2017
Earnings Scheduled For December 21, 2016
Diagnostic Kit Maker Tests Resistance In Base; Gets Rating Upgrade (Investor's Business Daily)
Related VIVO
Mid-Afternoon Market Update: Seagate Climbs On Strong Q2 Results; Meridian Bioscience Shares Plummet
15 Biggest Mid-Day Losers For Wednesday
Meridian Bioscience Inc. (Nasdaq: VIVO) to Ring The Nasdaq Stock Market Opening Bell (GuruFocus)

Below are the top small-cap diagnostic substances stocks on the NYSE and the NASDAQ in terms of revenue.

The trailing-twelve-month revenue at Neogen (NASDAQ: NEOG) is $179.10 million. Neogen had $61.33 million in total cash for the latest quarter.

The trailing-twelve-month revenue at Meridian Bioscience (NASDAQ: VIVO) is $169.11 million. Meridian Bioscience's PEG ratio is 1.37.

The trailing-twelve-month revenue at Abaxis (NASDAQ: ABAX) is $156.60 million. Abaxis's ROE for the same period is 7.97%.

The trailing-twelve-month revenue at Quidel (NASDAQ: QDEL) is $136.97 million. Quidel had $21.56 million in total cash for the latest quarter.

Posted-In: Diagnostic Substances Industry Highest Revenue small-capTrading Ideas


Related Articles (ABAX + NEOG)

View Comments and Join the Discussion!